Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100XUKD
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 85
MetricValuePeriodScopeSource row
Revenue¥84m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥193m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥190m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥126m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥162m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.0bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥846m2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥1.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥848m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥710m2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥754m2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥887m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥866m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥858m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥1.1bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥860m2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥847m2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥760m2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥913m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.4bnat 2024-12-31StandaloneAssets
Total assets¥2.5bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥387mat 2025-12-31StandaloneLiabilities
Total liabilities¥270mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.3bnat 2025-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2024-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.3bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥931mat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥989m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥866m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥779m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥718m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥817m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥27m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥18m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥56m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥62m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥110m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥200m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥855m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.8bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥882m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥397m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-31.822025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-25.722024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-29.432023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥35.37at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥62.1at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥68.08at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥47.26at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio76.0%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.5%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.9%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued35,557,719at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued34,666,419at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued31,459,019at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees36at 2025-12-31StandaloneNumber of employees
Employees38at 2024-12-31StandaloneNumber of employees
Employees35at 2023-12-31vStandaloneNumber of employees
Employees30at 2022-12-31vStandaloneNumber of employees
Employees44at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-01-01 → 2025-12-31¥229,000
Reconciling Itemsreconcilingsegment assetsat 2025-12-31¥1.4bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-12-31−¥218m
Cell Sheet Regenerative Medicinereportable segmentcapex2025-01-01 → 2025-12-31¥488,000
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2025-12-3120 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2025-01-01 → 2025-12-31¥2m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2025-01-01 → 2025-12-31¥2m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2025-12-31¥96m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2025-01-01 → 2025-12-31−¥723m
Laboratory Consumables And Equipmentreportable segmentcapex2025-01-01 → 2025-12-31¥52m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2025-12-3111 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2025-01-01 → 2025-12-31¥82m
Laboratory Consumables And Equipmentreportable segmentrevenue external2025-01-01 → 2025-12-31¥82m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2025-12-31¥112m
Laboratory Consumables And Equipmentreportable segmentsegment profit2025-01-01 → 2025-12-31−¥105m
—segment totalcapex2025-01-01 → 2025-12-31¥52m
—segment totalrevenue2025-01-01 → 2025-12-31¥84m
—segment totalrevenue external2025-01-01 → 2025-12-31¥84m
—segment totalsegment assetsat 2025-12-31¥208m
—segment totalsegment profit2025-01-01 → 2025-12-31−¥828m
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥16m
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥230m
Cell Sheet Regenerative Medicinereportable segmentrevenue2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2024-12-31¥70m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2024-01-01 → 2024-12-31−¥596m
Laboratory Consumables And Equipmentreportable segmentcapex2024-01-01 → 2024-12-31¥2m
Laboratory Consumables And Equipmentreportable segmentrevenue2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2024-12-31¥121m
Laboratory Consumables And Equipmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥21m
—segment totalcapex2024-01-01 → 2024-12-31¥2m
—segment totalrevenue2024-01-01 → 2024-12-31¥193m
—segment totalrevenue external2024-01-01 → 2024-12-31¥193m
—segment totalsegment assetsat 2024-12-31¥191m
—segment totalsegment profit2024-01-01 → 2024-12-31−¥616m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 989
ItemContextValueUnit
Purchase of intangible assets inv cfCurrentYearDuration_NonConsolidatedMember-488000JPY
Net cash provided by used in investment activitiesPrior1YearDuration_NonConsolidatedMember-18367000JPY
Net cash provided by used in investment activitiesCurrentYearDuration_NonConsolidatedMember-26717000JPY
Repayment of long term loans payable fin cfPrior1YearDuration_NonConsolidatedMember-7500000JPY
Repayment of long term loans payable fin cfCurrentYearDuration_NonConsolidatedMember-10834000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember862979000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember207698000JPY
Proceeds from issuance of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Proceeds from issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember3440000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember855479000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember200304000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-28992000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-815389000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember2163292000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember2134299000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember2134299000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember1318909000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember573317000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember720052000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember22320000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember43110000JPY
Payroll and allowances sgaPrior1YearDuration_NonConsolidatedMember81822000JPY
Payroll and allowances sgaCurrentYearDuration_NonConsolidatedMember73846000JPY
Bonuses sgaPrior1YearDuration_NonConsolidatedMember20222000JPY
Bonuses sgaCurrentYearDuration_NonConsolidatedMember19759000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember51913000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember48234000JPY
Patent costs sgaPrior1YearDuration_NonConsolidatedMember20504000JPY
Patent costs sgaCurrentYearDuration_NonConsolidatedMember16191000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember1971000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember1939000JPY
Write downs of inventoriesPrior1YearDuration_NonConsolidatedMember1179000JPY
Write downs of inventoriesCurrentYearDuration_NonConsolidatedMember1687000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember192059000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember193277000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember193277000JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember192059000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember193277000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember193277000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember-20535000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-595521000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass